In a meta-analysis by Abdel-Rahman et al., patients treated with these therapies reported a greater risk of hypophysitis, hypo- and hyperthyroidism, and adrenal insufficiency, but without a specific association with incidence, severity, and distinct tumors or drugs (CTLA-4 vs. PD-1) [63]. Here, CTLA4 is linked to hypophysitis.